3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.
Primary endpoint(s) modified
Also in this update: Enrollment closed, study ongoing; Interventions modified
Aura BiosciencesNot specified NCT07421739 Registry history of NCT07421739 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 66 → 53 locations
Aura BiosciencesPhase 3 NCT06007690 Registry history of NCT06007690 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 10 → 13 locations
Aura BiosciencesPhase 2 NCT06643884 Registry history of NCT06643884 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 1 | |
| Phase 2 | 1 | |
| Phase 3 | 1 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06007690 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of… | Choroidal Melanoma | Active, Not Recruiting | 2026-10-13 |
| Phase 2 | ||||
| NCT06643884 | Suprachoroidal Administration in Subjects With Metastases to the Choroid | Eye Cancer | Recruiting | 2026-10-08 |
| Phase 1 | ||||
| NCT05483868 | A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | Non-muscle-invasive Bladder Cancer | Active, Not Recruiting | 2026-08-06 |
| Not specified | ||||
| NCT07421739 | Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301… | Choroidal Melanoma | Active, Not Recruiting | 2026-10-15 |
| NCT07338968 | A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early… | Choroidal Melanoma | Enrolling by Invitation | 2026-08-19 |
| NCT03941379 | A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | Choroidal Melanoma | Active, Not Recruiting | 2026-05-22 |
Melanoma (4) · Bladder Cancer (1)